Jonathan Corren, MD; Monica Kraft, MD; Reynold A. Panettieri, Jr, MD
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from AstraZeneca.
Reynold A. Panettieri, Jr., MD (Moderator)
Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
Emeritus Professor of Medicine, University of Pennsylvania
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, New Jersey
Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine
University of California, Los Angeles
Medical Director, Jonathan Corren M.D. and Associates
Los Angeles, California
Monica Kraft, MD
Professor of Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
The educational design of this activity addresses the needs of pulmonologists, clinical immunologists, and other specialist clinicians who treat patients with severe asthma.
This Interactive Exchange™ enduring activity begins with severe asthma expert presentations that impart foundational information─including key upstream inflammatory pathways, the role of the epithelium in asthma development, mechanisms underlying characteristic phenotypes, and the rationale for targeted biologic therapies─for the interactive discussions that follow. Faculty focus on key topics, such as recent clinical trial evidence for emerging pharmacotherapies that target type 2 (T2)–low disease, evolving evidence-based treatment algorithms, and potential strategies for effectively managing patients with uncontrolled, severe disease. This multimedia experience ensures the delivery of shared experiences surrounding challenging clinical topics in today’s severe asthma landscape.
After completing this activity, the participant should be better able to:
- Describe clinically relevant pathophysiologic processes in severe asthma, including implications for new targeted treatment options
- Comprehensively assess patients with asthma for disease severity, lung function, and treatment responses
- Discuss the mechanisms of action and clinical profiles of new and emerging targeted therapies for severe asthma
- Individualize treatment regimens for patients with severe asthma based on symptoms, phenotypes, and patient preferences
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Integritas Communications Contact Information
For all other questions about this activity, please contact Integritas Communications at email@example.com.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 75% or better on the posttest, and complete the program evaluation.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC; Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose US, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, Teva Pharmaceutical Industries Ltd.; Speakers Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC; Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC
Reynold A. Panettieri, Jr, MD
Grant/Research Support: AstraZeneca plc, Equillium, Inc., Evelo Biosciences, Inc., Genentech, Inc., Johnson & Johnson, Maven, MedImmune, LLC, Novartis Pharmaceuticals Corporation, OptiKira, LLC, Theravance Biopharma, Inc.; Consultant/Advisory Board: AstraZeneca plc, Bayer AG, Equillium Inc., Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, Theravance Biopharma, Inc.; Speakers Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
The following planners and managers have no relevant financial relationships with ineligible companies:
Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Celeste Collazo, MD, Rose O'Connor, PhD, CHCP, Jim Kappler, PhD
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Term of Offering
This activity was released on June 25, 2021 and is valid for one year. Requests for credit must be made no later than June 25, 2022.
Microsoft Windows 2000 SE or above.
Internet Explorer (v5.5 or greater), Chrome or Firefox MAC
MAC OS 10.2.8:
Internet Explorer is not supported on the Macintosh.